Citius Pharmaceuticals (CTXR) News Today $2.32 +0.22 (+10.29%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral CapitalJuly 2 at 2:34 AM | americanbankingnews.comCitius Pharmaceuticals Inc News (CTXR) - Investing.comJuly 1 at 11:46 AM | investing.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $54.50 Consensus Price Target from BrokeragesJune 23, 2025 | americanbankingnews.comCitius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025June 17, 2025 | prnewswire.comCitius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq RulesJune 12, 2025 | prnewswire.comCitius Pharma Announces Direct OfferingJune 11, 2025 | nasdaq.comCitius Pharmaceuticals expands authorized sharesJune 10, 2025 | investing.comCitius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq RulesJune 10, 2025 | prnewswire.comCitius Pharmaceuticals Stock Is Soaring Monday: What's Going On?June 9, 2025 | benzinga.comMaxim Group Downgrades Citius Pharmaceuticals (CTXR)May 24, 2025 | msn.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | prnewswire.comCitius Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 5, 2025 | prnewswire.comCitius Pharmaceuticals target adjusted to $4 for split at H.C. WainwrightApril 12, 2025 | markets.businessinsider.comCitius Pharmaceuticals announces $2M registered direct offering of common stockApril 2, 2025 | markets.businessinsider.comCitius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common StockApril 1, 2025 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdateFebruary 14, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology announce J-Code issued for LymphirFebruary 6, 2025 | markets.businessinsider.comCitius Pharma's LYMPHIR gains permanent J-code for billingFebruary 6, 2025 | msn.comCitius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid ServicesFebruary 6, 2025 | prnewswire.comCitius Pharmaceuticals announces $3M registered direct offering priced ATMJanuary 8, 2025 | markets.businessinsider.comCitius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesJanuary 8, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025January 7, 2025 | prnewswire.comCitius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic AlternativesJanuary 6, 2025 | prnewswire.comD. Boral Capital Upgrades Citius Pharmaceuticals (CTXR)December 30, 2024 | msn.comCitius Pharmaceuticals upgraded to Buy from Hold at D. Boral CapitalDecember 30, 2024 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides ...December 28, 2024 | gurufocus.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business UpdateDecember 27, 2024 | prnewswire.comCitius Pharma Held Productive FDA Meeting To Discuss Phase 3 Mino-Lok Program, Pathway To ApprovalNovember 25, 2024 | markets.businessinsider.comCitius Pharmaceuticals reports ‘constructive’ FDA Type C meeting on Mino-LokNovember 25, 2024 | markets.businessinsider.comCitius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNovember 25, 2024 | prnewswire.comD. Boral Capital Downgrades Citius Pharmaceuticals (CTXR)November 23, 2024 | msn.comCitius Pharmaceuticals downgraded to Hold from Buy at D. Boral CapitalNovember 23, 2024 | markets.businessinsider.comCitius Pharmaceuticals announces 1-for-25 reverse stock splitNovember 23, 2024 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock SplitNovember 22, 2024 | prnewswire.comCitius Pharmaceuticals Announces Closing of $3 Million Registered Direct OfferingNovember 18, 2024 | prnewswire.comCitius Pharmaceuticals Announces $3 Million Registered Direct OfferingNovember 15, 2024 | prnewswire.comEquities Analysts Issue Forecasts for CTXR FY2024 EarningsNovember 14, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CTXR Q1 Earnings?November 13, 2024 | marketbeat.comBuy Rating for Citius Pharmaceuticals: Promising Clinical Results and Strong Financial OutlookNovember 13, 2024 | markets.businessinsider.comCitius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy RatingNovember 13, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Citius Pharmaceuticals (NASDAQ:CTXR)November 12, 2024 | marketbeat.comCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid TumorsNovember 11, 2024 | prnewswire.comCitius Pharma (NASDAQ:CTXR) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short InterestSeptember 30, 2024 | marketbeat.comArmistice Capital LLC Acquires Shares of 10,156,000 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)September 26, 2024 | marketbeat.comCitius Pharmaceuticals defers FDA milestone paymentSeptember 15, 2024 | uk.investing.comCitius Pharmaceuticals faces potential Nasdaq delistingSeptember 13, 2024 | uk.investing.comCitius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologySeptember 5, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Drop in Short InterestSeptember 2, 2024 | marketbeat.com Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address CTXR Media Mentions By Week CTXR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼0.470.90▲Average Medical News Sentiment CTXR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼31▲CTXR Articles Average Week Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies INCR News Today IGMS News Today IMUX News Today IZTC News Today IKNA News Today MNOV News Today ADAP News Today ICCC News Today CLSD News Today PYRGF News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
